Bank of America Boosts Danaher (NYSE:DHR) Price Target to $275.00

Danaher (NYSE:DHR) had its price target lifted by Bank of America from $270.00 to $275.00 in a research report released on Wednesday, Benzinga reports. The brokerage currently has a neutral rating on the conglomerate’s stock.

DHR has been the subject of several other research reports. Barclays upped their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an equal weight rating in a research report on Wednesday, April 24th. Robert W. Baird upped their price target on Danaher from $259.00 to $271.00 and gave the stock an outperform rating in a research report on Wednesday, April 24th. Evercore ISI lowered their price target on Danaher from $266.00 to $260.00 and set an outperform rating for the company in a report on Tuesday, July 2nd. Jefferies Financial Group started coverage on shares of Danaher in a report on Monday, June 3rd. They set a buy rating and a $295.00 price objective on the stock. Finally, TD Cowen upped their target price on Danaher from $280.00 to $290.00 and gave the company a buy rating in a research report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $276.88.

Danaher Trading Up 1.5 %

NYSE DHR opened at $274.13 on Wednesday. Danaher has a 12 month low of $182.09 and a 12 month high of $277.72. The company’s 50-day moving average price is $255.16 and its 200-day moving average price is $249.09. The stock has a market cap of $197.98 billion, a PE ratio of 46.46, a PEG ratio of 4.11 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.51 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company posted $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. Equities research analysts forecast that Danaher will post 7.6 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 26th. Investors of record on Friday, June 28th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, June 28th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Buying and Selling

In other news, CFO Matthew Mcgrew sold 46,377 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $7,441,441.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CFO Matthew Mcgrew sold 46,377 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $253.05, for a total value of $11,735,699.85. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $7,441,441.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the transaction, the director now owns 116,202 shares in the company, valued at $28,304,483.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 84,775 shares of company stock worth $21,802,690. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Several hedge funds and other institutional investors have recently made changes to their positions in DHR. Cape Investment Advisory Inc. acquired a new stake in shares of Danaher in the 4th quarter worth $25,000. Tsfg LLC raised its stake in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the 2nd quarter valued at about $25,000. Wetzel Investment Advisors Inc. purchased a new stake in shares of Danaher in the 4th quarter valued at approximately $29,000. Finally, Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter worth approximately $30,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.